OpenAI is lobbying for an expanded role of AI in life sciences, according to an Axios exclusive that puts corporate influence right where the bottlenecks are: inside the long, expensive pipeline that decides which drugs make it from research to approval in the United States. The report says that process often takes 12 to 15 years, a timeline that leaves ordinary people waiting while institutions and firms fight over who gets to steer the next phase of medicine.
Who Has the Power
Axios reported that OpenAI is lobbying for a broader role in life sciences. That is the central fact: a powerful AI company is not just building tools, but pushing to shape how those tools are used in a field tied directly to health, research, and approval systems. The article frames this as an effort to expand AI’s place in the life sciences, which means the question is not simply what AI can do, but who gets to decide where it enters the pipeline.
The report places that lobbying against the backdrop of a drug-development process in the United States that often takes 12 to 15 years from research to approval. That long delay is the terrain on which corporate actors now move, promising speed while the underlying system remains a maze of gatekeeping, paperwork, and institutional control.
What They Call Progress
Axios also referred to Eroom’s Law, described as a reverse of Moore’s Law. In the article’s telling, the concept suggests that research progress slows as scientists must learn prior work. That is the kind of structural drag that large institutions love to describe as a technical problem, even though it is also a product of how knowledge is organized, owned, and parceled out through hierarchy.
The piece framed AI as a potential accelerant for life sciences. It said AI “has nothing but time” to advance research. That line captures the pitch in miniature: a machine system with endless patience, positioned as the answer to a process that takes more than a decade and a half to move from lab to approval. The promise is speed, but the power remains concentrated in the hands of the actors lobbying to define the terms.
The Bottleneck Is the System
The article’s facts point to a familiar arrangement: a slow-moving approval structure, a corporate AI company seeking a bigger role, and a research environment where progress is measured against prior work that must be learned, absorbed, and surpassed. The delay is not just a scientific inconvenience. It is the environment in which institutions justify new layers of control, new intermediaries, and new claims that technology will solve what hierarchy has made sluggish.
OpenAI’s lobbying effort, as reported by Axios, sits inside that arrangement. The company is not described as offering mutual aid or horizontal organizing. It is lobbying, which means trying to influence the terms of power from above. The article does not describe any grassroots response, any community-led alternative, or any direct action from people affected by the 12-to-15-year drag of drug development. What it does show is the familiar corporate move: a powerful firm stepping toward the center of a system already built to filter access and concentrate decision-making.
The Axios report presents AI as a tool that could help life sciences move faster. But the facts in the article also show the deeper structure: a long approval process, a theory about slowing progress, and a company lobbying for a larger seat at the table. In the language of the apparatus, that is called innovation. In practice, it is another contest over who gets to command the machinery of research and medicine.